Canada Pension Plan Investment Board Acquires Shares of 52,834 Medpace Holdings, Inc. $MEDP

Key Points

• Canada Pension Plan Investment Board acquired 52,834 Medpace shares worth approximately $28 million, giving it a 0.19% stake. Institutional investors collectively own 77.98% of the company.
• Medpace exceeded quarterly expectations, reporting $4.25 EPS and $707.33 million in revenue, with revenue up 17.2% year over year. The stock opened at $600.65, near its $677.90 one-year high.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and a $584.18 target price, while insiders sold about $81.7 million of stock over the past 90 days.

Canada Pension Plan Investment Board acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 52,834 shares of the company's stock, valued at approximately $27,980,000. Canada Pension Plan Investment Board owned about 0.19% of Medpace as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in MEDP. NewEdge Advisors LLC lifted its holdings in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock valued at $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock valued at $24,929,000 after purchasing an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. raised its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares during the period. Sivia Capital Partners LLC bought a new position in shares of Medpace in the second quarter valued at about $296,000. Finally, M&T Bank Corp lifted its stake in shares of Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company's stock worth $295,000 after buying an additional 31 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Price Performance

Medpace stock opened at $600.65 on Friday. The stock's fifty day moving average price is $565.33 and its two-hundred day moving average price is $494.55. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The firm has a market cap of $16.76 billion, a PE ratio of 35.21, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company's revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

MEDP has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Mizuho raised their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Royal Bank Of Canada boosted their price objective on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a report on Friday, July 24th. Weiss Ratings raised Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Finally, TD Cowen increased their target price on Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, Medpace presently has a consensus rating of "Hold" and a consensus target price of $584.18.

Insider Buying and Selling

In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of the company's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the completion of the sale, the director owned 3,798 shares of the company's stock, valued at $2,302,157.70. This represents a 65.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Brian T. Carley sold 5,000 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director owned 27,825 shares in the company, valued at $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 133,821 shares of company stock worth $81,748,135 in the last ninety days. 20.50% of the stock is owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source